Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast

April 15, 2014
Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S
Conference|Annual Meeting of the American Radium Society (ARS)

Due to the rarity of Paget disease (PD), the role of breast conserving surgery (BCS) and radiation therapy (RT) is not fully defined. The specific aims of this analysis are to study national patterns of care in the local management of PD and to determine breast cancer–specific survival (BCSS) by type of treatment in a large population-based cohort.

Mariam P. Korah, MD, Eugene Chung, MD, PhD, JD; Department of Radiation Oncology, USC Keck School of Medicine

Purpose and Objectives: Paget disease (PD) of the breast is a condition characterized by infiltration of the epidermis of the nipple with neoplastic cells with or without an underlying malignancy of the breast parenchyma. Due to the rarity of PD, the role of breast conserving surgery (BCS) and radiation therapy (RT) is not fully defined. The specific aims of this analysis are to study national patterns of care in the local management of PD and to determine breast cancer–specific survival (BCSS) by type of treatment in a large population-based cohort.

Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried for women ≥ 20 years of age diagnosed with Tis–T2 N0 M0 mammary PD who underwent definitive surgery +/– RT from 1998–2010, with minimum follow-up of 6 months. The cohort was stratified by type of treatment into four groups: BCS, BCS + RT, mastectomy (M), or M + RT. Clinical covariates were compared between the groups using the chi-square test. Cox multivariable regression analyses were performed to determine predictors of BCSS. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test.

Results: The median follow-up time was 5 years (range: 0.5–12.9 yr). The study cohort comprised 1,509 women, most of whom were ≥ 50 years (79%). The distribution of underlying histologic subtypes was as follows: PD with infiltrating ductal carcinoma (IDC, 43%), PD with ductal carcinoma in situ (DCIS, 46%), and PD with no underlying tumor (11%). High-grade histology was identified in 48% of patients, with estrogen receptor and progesterone receptor positivity in 27% and 18% of patients, respectively. Allocation to treatment groups was as follows: BCS (n = 200), BCS + RT (n = 216), M (n = 1,046), and M + RT (n = 47). Mastectomy rates were highest among patients with PD-IDC (87%). Rates of mastectomy were 74% in the early study period (1998–2004) vs 71% in the latter study period (2005–2010) (P = .12). Overall, lymph node sampling or dissection was performed in 72% of patients: 92% of those with PD-IDC, 61% of those with PD-DCIS, and 44% of those with PD and no demonstrable tumor. BCSS at 5 and 8 years was 93% and 91% for PD-IDC, 98% and 96% for PD-DCIS, and 95% and 95% for PD without underlying tumor, respectively. BCSS was higher among patients in the BCS + RT group (94% at 8 years) compared with those who received BCS alone (91% at 8 years) (P = .54). No difference in BCSS was noted between the BCS + RT and M-alone groups (94% at 8 years) (P = .98). After adjusting for patient and tumor characteristics, no differences were observed in BCSS based on type of surgery (P = .61). Patients who required postmastectomy RT had poorer pretreatment tumor characteristics and inferior BCSS (83% at 8 years).

Conclusions: This population-based analysis shows that mastectomy with lymph node assessment is the most commonly employed approach for local disease management in early-stage PD. Rates of mastectomy have remained relatively constant throughout the study era. Despite conferring comparable rates of BCSS to mastectomy, BCS + RT appears to be underutilized in the management of PD of the breast.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content
Advertisement

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Roman Fabbricatore
May 31st 2025
Article

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.


40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato
May 31st 2025
Article
Related Content
Advertisement

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Roman Fabbricatore
May 31st 2025
Article

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.


40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato
May 31st 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.